The POU4F2/Brn-3b transcription factor is required for the hypertrophic response to angiotensin II in the heart

被引:0
作者
Laura Mele
Lauren J. Maskell
Daniel J. Stuckey
James E. Clark
Richard J. Heads
Vishwanie S. Budhram-Mahadeo
机构
[1] UCL Institute of Cardiovascular Science,Molecular Biology Development and Disease
[2] Division of Medicine,Centre for Advanced Biomedical Imaging (CABI)
[3] UCL Faculty of Medical Sciences,School of Cardiovascular Medicine and Sciences
[4] Faculty of Life Sciences and Medicine,undefined
[5] King’s College,undefined
来源
Cell Death & Disease | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Adult hearts respond to increased workload such as prolonged stress or injury, by undergoing hypertrophic growth. During this process, the early adaptive responses are important for maintaining cardiac output whereas at later stages, pathological responses such as cardiomyocyte apoptosis and fibrosis cause adverse remodelling, that can progress to heart failure. Yet the factors that control transition from adaptive responses to pathological remodelling in the heart are not well understood. Here we describe the POU4F2/Brn-3b transcription factor (TF) as a novel regulator of adaptive hypertrophic responses in adult hearts since Brn-3b mRNA and protein are increased in angiotensin-II (AngII) treated mouse hearts with concomitant hypertrophic changes [increased heart weight:body weight (HW:BW) ratio]. These effects occur specifically in cardiomyocytes because Brn-3b expression is increased in AngII-treated primary cultures of neonatal rat ventricular myocytes (NRVM) or foetal heart-derived H9c2 cells, which undergo characteristic sarcomeric re-organisation seen in hypertrophic myocytes and express hypertrophic markers, ANP/βMHC. The Brn-3b promoter is activated by known hypertrophic signalling pathways e.g. p42/p44 mitogen-activated protein kinase (MAPK/ERK1/2) or calcineurin (via NFAT). Brn-3b target genes, e.g. cyclin D1, GLUT4 and Bax, are increased at different stages following AngII treatment, supporting distinct roles in cardiac responses to stress. Furthermore, hearts from male Brn-3b KO mutant mice display contractile dysfunction at baseline but also attenuated hypertrophic responses to AngII treatment. Hearts from AngII-treated male Brn-3b KO mice develop further contractile dysfunction linked to extensive fibrosis/remodelling. Moreover, known Brn-3b target genes, e.g. GLUT4, are reduced in AngII-treated Brn-3b KO hearts, suggesting that Brn-3b and its target genes are important in driving adaptive hypertrophic responses in stressed heart.
引用
收藏
相关论文
共 136 条
[1]  
Frey N(2003)Cardiac hypertrophy: the good, the bad, and the ugly Annu. Rev. Physiol. 65 45-79
[2]  
Olson EN(2001)Molecular mechanism of cardiac hypertrophy and development Jpn. Circ. J. 65 353-358
[3]  
Komuro I(1998)Pathological versus physiological left ventricular hypertrophy: a review J. Sports Sci. 16 129-141
[4]  
Richey PA(1989)Molecular adaptation to pressure overload in human and rat hearts J. Mol. Cell Cardiol. 21 91-101
[5]  
Brown SP(1996)Myocyte death in heart failure Curr. Opin. Cardiol. 11 245-251
[6]  
Yazaki Y(2001)Cytoplasmic signaling pathways that regulate cardiac hypertrophy Annu. Rev. Physiol. 63 391-426
[7]  
Tsuchimochi H(1999)Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy Circulation 100 2449-2454
[8]  
Kurabayashi M(2004)Calcium-calcineurin signaling in the regulation of cardiac hypertrophy Biochem. Biophys. Res. Commun. 322 1178-1191
[9]  
Komuro I(2004)Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy Circ. Res. 94 110-118
[10]  
Anversa P(2000)Molecular basis of cardiac hypertrophy Z. Kardiol. 89 1-6